Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

Published 2020 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
Authors
Keywords
Anti–PD-1, Checkpoint inhibitors, Melanoma, Renal cell carcinoma, Lung cancer, Toxicities, Survivorship, Quality of life, Pembrolizumab, Nivolumab
Journal
EUROPEAN JOURNAL OF CANCER
Volume 135, Issue -, Pages 211-220
Publisher
Elsevier BV
Online
2020-06-27
DOI
10.1016/j.ejca.2020.05.005

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.